Chinese PLA General Hospital
301hospital.com.cnLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
543
Active
157
Phase 3
13
Total enrollment
1,280,587
Pipeline matrix
Showing 40 of 116 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Saline | — | — | — | — | 2 | ||
| Acemetacin | — | — | — | — | — | 1 | |
| Keluoxin | — | — | — | — | — | 1 | |
| Keluoxin Capsule Simulants | — | — | — | — | — | 1 | |
| Irbesartan | — | — | — | — | — | 1 | |
| Ruxolitinib, Decitabine | — | — | — | — | — | 1 | |
| The rHuEPO Monotherapy Group | — | — | — | — | — | 1 | |
| The Pegmolesatide and Roxadustat Combination Therapy Group | — | — | — | — | — | 1 | |
| The Pegmolesatide Monotherapy Group | — | — | — | — | — | 1 | |
| Eculizumab+IVMP | — | — | — | — | — | 1 | |
| IVIG+IVMP | — | — | — | — | — | 1 | |
| IVMP | — | — | — | — | — | 1 | |
| Esketamine hydrochloride | — | — | — | — | — | 1 | |
| Huaier granule | — | — | — | — | — | 1 | |
| Renin-angiotensin-aldosterone system inhibitors | — | — | — | — | — | 1 | |
| Ciclosporin soft | — | — | — | — | — | 1 | |
| Chemotherapy drug | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | 16 | ||
| Fludarabine | — | — | — | — | 14 | ||
| Albumin-bound paclitaxel | — | — | — | — | — | 3 | |
| Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor | — | — | — | — | — | 3 | |
| CD70-targeting CAR-T cells | — | — | — | — | — | 2 | |
| Chidamide; Decitabine; Anti-PD-1 Antibody | — | — | — | — | — | 2 | |
| CAR19TIF cells | — | — | — | — | — | 2 | |
| Amimestrocel | — | — | — | — | — | 2 | |
| Camrelizumab | — | — | — | — | — | 4 | |
| S-1 | — | — | — | — | — | 3 | |
| Nab paclitaxel | — | — | — | — | — | 2 | |
| "3+7" | — | — | — | — | — | 2 | |
| Rituximab | — | — | — | — | — | 2 | |
| surufatinib + camrelizumab + nab-paclitaxel + S-1 | — | — | — | — | — | 1 | |
| nab-paclitaxel + gemcitabine | — | — | — | — | — | 1 | |
| Allogenic CD19-CAR-γδT cell | — | — | — | — | — | 1 | |
| GPC3-CART cells | — | — | — | — | — | 1 | |
| Fludarabine Phosphate for | — | — | — | — | — | 1 | |
| Cyclophosphamide for | — | — | — | — | — | 1 | |
| MSC-IFNα | — | — | — | — | — | 1 | |
| Anti-PD-1 monoclonal antibody | — | — | — | — | — | 1 | |
| Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody | — | — | — | — | — | 1 | |
| RetroNectin active Killer cells | — | — | — | — | — | 1 |
76 more active programs hidden
Next readouts
- 2018-10
- 2022-12
- 2024-12-16
- 2024-12-30
- 2024-12-30
- 2025-01-31
- 2025-09
- 2025-09-01
- 2025-09-01
- 2025-09-28
Top conditions
- Sepsis20
- Hepatocellular Carcinoma13
- Gastric Cancer12
- Solid Tumor9
- Anxiety8
- Depression7
- Pancreatic Cancer7
- Lymphoma7
Frequently asked questions about Chinese PLA General Hospital
- How many clinical trials does Chinese PLA General Hospital have on ClinicalTrials.gov?
- Chinese PLA General Hospital is listed as the lead sponsor on 543 clinical trials in ClinicalTrials.gov, 157 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Chinese PLA General Hospital's trials are in Phase 3?
- 13 of Chinese PLA General Hospital's trials are in Phase 3, spread across 116 active drug programs.
- What therapeutic areas does Chinese PLA General Hospital focus on?
- Chinese PLA General Hospital's most-studied conditions on ClinicalTrials.gov are Sepsis, Hepatocellular Carcinoma, Gastric Cancer, Solid Tumor, Anxiety.
- When are Chinese PLA General Hospital's next clinical trial readouts?
- Chinese PLA General Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas”, expected around 2018-10.